PMC:6909918 / 22513-23147
Annnotations
{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/6909918","sourcedb":"PMC","sourceid":"6909918","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6909918","text":"In the present study, indirect comparisons of the three drugs showed that fruquintinib demonstrated a significant superiority for PFS when compared with TAS-102, with a similar finding also shown in the indirect comparison of DCR. These improved outcomes suggested that fruquintinb might be a better choice in selected pretreated patients with mCRC. Also, this study showed that the Eastern Cooperative Oncology Group Performance Status (ECOG PS) status of patients included in the CORRECT trial [4] (regorafenib, PS=0; 56.0%) was significantly improved when compared with patients in the FRESCO trial [7] (fruquintinib, PS=0; 27.4%).","tracks":[{"project":"2_test","denotations":[{"id":"31790382-23177514-69134735","span":{"begin":497,"end":498},"obj":"23177514"},{"id":"31790382-29946728-69134736","span":{"begin":603,"end":604},"obj":"29946728"}],"attributes":[{"subj":"31790382-23177514-69134735","pred":"source","obj":"2_test"},{"subj":"31790382-29946728-69134736","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93eca8","default":true}]}]}}